"Drug Substitution/adverse effects"[MAJR] - Search Results

Year	Number of Results
2010	3
2011	7
2012	12
2013	15
2014	6
2015	9
2016	22
2017	24
2018	28
2019	20
2020	17
2021	6
2022	3
2024	0

1

Switch-associated adverse events: focus on olanzapine.

Xu L, Krishnaswamy S. Xu L, et al. Australas Psychiatry. 2018 Dec;26(6):635-639. doi: 10.1177/1039856218810166. Epub 2018 Nov 8. Australas Psychiatry. 2018. PMID: 30407073 Review.

2

Overgangen fra digitoksin til digoksin i årene 2011–13.

Lien K, Spigset O, Westin AA, Slørdal L. Lien K, et al. Tidsskr Nor Laegeforen. 2018 Oct 1;138(15). doi: 10.4045/tidsskr.18.0093. Print 2018 Oct 2. Tidsskr Nor Laegeforen. 2018. PMID: 30277048 Free article. Norwegian.

3

Quantification of Adverse Drug Reactions Related to Drug Switches in The Netherlands.

Glerum PJ, Maliepaard M, de Valk V, Scholl JHG, van Hunsel FPAM, van Puijenbroek EP, Burger DM, Neef K. Glerum PJ, et al. Clin Transl Sci. 2020 May;13(3):599-607. doi: 10.1111/cts.12746. Epub 2020 Feb 12. Clin Transl Sci. 2020. PMID: 32052597 Free PMC article.

4

Switching medication products during the treatment of psychiatric illness.

Blier P, Margolese HC, Wilson EA, Boucher M. Blier P, et al. Int J Psychiatry Clin Pract. 2019 Mar;23(1):2-13. doi: 10.1080/13651501.2018.1508724. Epub 2019 Feb 8. Int J Psychiatry Clin Pract. 2019. PMID: 30732488 Review.

5

Prescription switching: Rationales and risks.

Kirby MG, Allchorne P, Appanna T, Davey P, Gledhill R, Green JSA, Greene D, Rosario DJ. Kirby MG, et al. Int J Clin Pract. 2020 Jan;74(1):e13429. doi: 10.1111/ijcp.13429. Epub 2019 Oct 7. Int J Clin Pract. 2020. PMID: 31573733

6

[Digitization ad modum the Norwegian Medicines Agency].

Slørdal L, Eggen AE. Slørdal L, et al. Tidsskr Nor Laegeforen. 2016 Nov 8;136(20):1700. doi: 10.4045/tidsskr.16.0810. eCollection 2016 Nov. Tidsskr Nor Laegeforen. 2016. PMID: 27830897 Free article. Norwegian. No abstract available.

7

The safety of switching between therapeutic proteins.

Ebbers HC, Muenzberg M, Schellekens H. Ebbers HC, et al. Expert Opin Biol Ther. 2012 Nov;12(11):1473-85. doi: 10.1517/14712598.2012.711308. Epub 2012 Jul 31. Expert Opin Biol Ther. 2012. PMID: 22849511 Review.

8

Switching between P2Y₁₂ inhibitors: Rationale, methods, and expected consequences.

Capranzano P, Capodanno D. Capranzano P, et al. Vascul Pharmacol. 2019 May;116:4-7. doi: 10.1016/j.vph.2019.03.001. Epub 2019 Mar 12. Vascul Pharmacol. 2019. PMID: 30876967 Review.

9

Switching immunoglobulin products, what are the implications? Result of 2018 census of immunology centres.

Bethune C, Herriot R. Bethune C, et al. Clin Med (Lond). 2019 May;19(3):201-204. doi: 10.7861/clinmedicine.19-3-201. Clin Med (Lond). 2019. PMID: 31092511 Free PMC article. Review.

10

[Levothyroxine and the problem of interchangeability of drugs with narrow therapeutic index].

Ward LS. Ward LS. Arq Bras Endocrinol Metabol. 2011 Oct;55(7):429-34. doi: 10.1590/s0004-27302011000700001. Arq Bras Endocrinol Metabol. 2011. PMID: 22147090 Review. Portuguese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

144 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Results by year